

TOP BIOTECH DEALS IN CHINA

MORE THAN \$12 BILLION in biopharma financing, alliances, IPOs, and new funds have been generated in China 1H 2020.

TYPE OF DEAL	# OF DEALS	TOTAL VALUE IN \$M
Alliances/BD&L	21	4,199
Financing	61	3,893
IPO/FPO	11	2,810
Funds	2	1,230
Totals	95	12,132

Sources: Biomedtracker and ChinaBio®

Deals from 01/01/2020 - 06/30/2020

TOP 5 PARTNERING & LICENSING DEALS GENERATED \$3.3B




DEAL VALUE IN \$M	PARTNERS
\$2,000	Innovent - Roche
\$570	Microbio Group, Oneness Biotech - Leo Pharma
\$330	Junshi Biosciences - Eli Lilly
\$190	Zai Lab - Regeneron
\$189	Apollomics - GlycoMimetics

Details:

- Innovent Bio, based in Suzhou, formed a R&D collaboration with Roche that has a potential value of over \$2 billion.
- Microbio Group and Oneness Biotech sold global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma to Leo Pharma, a Denmark dermatology company, in an agreement worth up to \$570 million.
- Junshi Biosciences and Eli Lilly and Company announced they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19.
- Zai Lab of Shanghai announced a collaboration with Regeneron worth up to \$190 million.
- Apollomics of Hangzhou announced a \$189 million deal for China rights to two GlycoMimetics immunotherapies.

TOP 5 FUNDRAISING DEALS RAISED OVER \$1B


AMOUNT RAISED IN \$M



Details:

- Everest Medicines, a Shanghai biopharma, announced a \$310 million Series C.
- Mabwell Biotech, based in Shanghai's Zhangjiang Hi-Tech Park, raised \$278.5 million in a Series A.
- Mabworks Biotech raised \$160 million in a Series C.
- Genor Biopharma, a Shanghai company, completed a \$160 million Series B.
- Zhiyun Health, an online health company focused on diabetes management, raised \$142 million in a combined C+ and D round.

TOP 5 IPOs RAISED OVER \$1.69B



AMOUNT RAISED IN IPO

Details:

- Legend Biotech of Shanghai priced its US IPO above the expected range at \$23 per ADS, raising \$424 million.
- Gan & Lee Pharma completed a Shanghai IPO that raised \$360 million for the company.
- AkesoBio, a Zhongshan developer of novel mono- and bi-specific antibodies, staged a \$335 million Hong Kong IPO.
- InnoCare Pharma of Beijing priced its Hong Kong IPO at the top end of its proposed range to raise \$288 million.
- Hygeia Healthcare Holdings, China's largest provider of radiotherapy services for oncology, staged a \$282 million IPO on the Hong Kong Exchange.

2 NEW FUNDS RAISED \$1.2B



INVESTMENT FUND RAISED IN \$M	VENTURE CAPITAL FIRM
\$1,001	Qiming Venture Partners
\$229	CICC Capital

Details:

- Qiming closed its seventh China-focused US dollar fund with \$1.1 billion for early stage healthcare and TMT investments.
- CICC Capital closed a \$229 million investment fund.

Tap into this vibrant life science market and engage with potential partners and investors at the largest China-focused partnering event during **CHINABIO® PARTNERING FORUM** Delivered Digitally.

LEARN MORE